Back to Search
Start Over
Osteosarcomas of the mandible: multidisciplinary management of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE.
- Source :
-
Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2013 Mar; Vol. 24 (3), pp. 824-31. Date of Electronic Publication: 2012 Nov 06. - Publication Year :
- 2013
-
Abstract
- Background: Mandibular osteosarcomas (MOS) mostly affect young adults. Their treatment is extrapolated from that of extragnathic osteosarcomas.<br />Material and Methods: A retrospective multicooperative group study was conducted to determine the impact of chemotherapy, adjuvant radiation therapy and surgery on outcomes and to identify prognostic factors. This ethical committee-approved study included a centralized review of histology slides and operative reports.<br />Results: Of 111 patients, 58.6% were male, median age 35 years (13%, ≤18 years). Histology was osteoblastic, chondroblastic, fibroblastic, conventional not otherwise specified and others in 39.6%, 30.6%, 8.1%, 12.6% and 8.0%, respectively. Pathological World Health Organisation grades were low, intermediate and high grade in 6.4%, 11.8% and 81.8%, respectively. Surgery was carried out for 94.5% of patients. Neoadjuvant chemotherapy (mixed protocols) was carried out in 93.1% of patients. Postoperative chemotherapy and radiotherapy were carried out in 54.7% and 23.8%, respectively. Median follow-up was 59.6 months (range). Five-year local control, metastasis-free, disease-free and overall survival rates were 64.6%, 68.9%, 53.2% and 69.2%, respectively. Survival was significantly associated with age, tumor size and surgery. Wide surgery with clear margins and free flap reconstruction was the strongest prognostic factor. Neoadjuvant chemotherapy improved disease-free and metastatic-free survival and increased clear margins rates from 50% to 68%. Intermediate grades behaved like high grades in terms of metastatic-free and disease-free survival.<br />Conclusion: This homogeneous series is the largest to date and emphasizes the major impact of clear margins and multidisciplinary management. Neoadjuvant chemotherapy improves disease-free survival and should be recommended for both high and intermediate grade MOS.
- Subjects :
- Adolescent
Adult
Aged
Aged, 80 and over
Child
Disease-Free Survival
Female
Humans
Kaplan-Meier Estimate
Male
Mandibular Neoplasms mortality
Mandibular Neoplasms pathology
Middle Aged
Multivariate Analysis
Neoplasm Recurrence, Local mortality
Osteosarcoma mortality
Osteosarcoma secondary
Proportional Hazards Models
Retrospective Studies
Treatment Outcome
Young Adult
Disease Management
Mandibular Neoplasms therapy
Neoplasm Recurrence, Local prevention & control
Osteosarcoma therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1569-8041
- Volume :
- 24
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- Annals of oncology : official journal of the European Society for Medical Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 23131392
- Full Text :
- https://doi.org/10.1093/annonc/mds507